Matches in SemOpenAlex for { <https://semopenalex.org/work/W1870673602> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W1870673602 endingPage "414" @default.
- W1870673602 startingPage "408" @default.
- W1870673602 abstract "This study was undertaken to define an escalated dose schedule of methotrexate, vinblastine, doxorubicin, and cisplatin (E-MVAC) with hematopoietic growth-factor support, to define the ability to deliver E-MVAC with recombinant human granulocyte colony-stimulating factor (rhG-CSF) on 21- and 14-day schedules, and to assess the ability of rhG-CSF to maintain dose-intensity over four cycles of chemotherapy.Twenty-three patients with transitional-cell carcinoma of the urothelium received E-MVAC in a phase I investigation. Patients were treated on an every-21-day (n = 19) or every-14-day schedule of administration (n = 4), with rhG-CSF support. Delivered dose-intensity was calculated at the completion of four cycles of therapy relative to the planned administration of conventional MVAC (relative dose-intensity [RDI]). Peripheral-blood progenitor cell kinetics in these patients were studied prospectively.Overall, the delivered RDI was 33% higher than the previously reported delivered dose-intensity of MVAC without hematopoietic support (140% for doxorubicin, 51% for cisplatin). Dose-intensity was well maintained through three cycles of therapy, after which leukopenia and thrombocytopenia became dose-limiting. Sixty-nine percent of patients with measurable disease responded, four (25%) with complete remissions. In five patients treated beyond the maximally tolerated dose (MTD), a 50- to 200-fold increase in G-CSF, granulocyte-macrophage CSF (GM-CSF), and interleukin-3 (IL-3)-responsive peripheral-blood progenitor cells over baseline was observed after 9 days of rhG-CSF administration.These findings demonstrate the feasibility and limitations of dose intensification of M-VAC with rhG-CSF. While the overall impact of the increased drug administration can only be assessed in randomized comparisons, the results of the present trial suggest that escalations of the components of the four-drug regimen are unlikely to improve significantly the outcome for patients with advanced urothelial tract tumors." @default.
- W1870673602 created "2016-06-24" @default.
- W1870673602 creator A5005818242 @default.
- W1870673602 creator A5020083811 @default.
- W1870673602 creator A5043344553 @default.
- W1870673602 creator A5051077215 @default.
- W1870673602 creator A5058359283 @default.
- W1870673602 creator A5059063118 @default.
- W1870673602 creator A5062295987 @default.
- W1870673602 creator A5064884168 @default.
- W1870673602 creator A5072850546 @default.
- W1870673602 creator A5090839925 @default.
- W1870673602 date "1993-03-01" @default.
- W1870673602 modified "2023-10-17" @default.
- W1870673602 title "Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer." @default.
- W1870673602 cites W1547869235 @default.
- W1870673602 cites W1980038158 @default.
- W1870673602 cites W1988919112 @default.
- W1870673602 cites W2023741846 @default.
- W1870673602 cites W2068358231 @default.
- W1870673602 cites W2089791300 @default.
- W1870673602 cites W2161668093 @default.
- W1870673602 cites W2170134215 @default.
- W1870673602 cites W2338649218 @default.
- W1870673602 cites W2341557816 @default.
- W1870673602 cites W2395088256 @default.
- W1870673602 cites W2397436995 @default.
- W1870673602 cites W2411866157 @default.
- W1870673602 cites W2417734794 @default.
- W1870673602 cites W2421671879 @default.
- W1870673602 cites W2493046514 @default.
- W1870673602 cites W2731419391 @default.
- W1870673602 cites W90009575 @default.
- W1870673602 doi "https://doi.org/10.1200/jco.1993.11.3.408" @default.
- W1870673602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7680373" @default.
- W1870673602 hasPublicationYear "1993" @default.
- W1870673602 type Work @default.
- W1870673602 sameAs 1870673602 @default.
- W1870673602 citedByCount "104" @default.
- W1870673602 countsByYear W18706736022012 @default.
- W1870673602 countsByYear W18706736022013 @default.
- W1870673602 countsByYear W18706736022014 @default.
- W1870673602 countsByYear W18706736022015 @default.
- W1870673602 countsByYear W18706736022018 @default.
- W1870673602 countsByYear W18706736022023 @default.
- W1870673602 crossrefType "journal-article" @default.
- W1870673602 hasAuthorship W1870673602A5005818242 @default.
- W1870673602 hasAuthorship W1870673602A5020083811 @default.
- W1870673602 hasAuthorship W1870673602A5043344553 @default.
- W1870673602 hasAuthorship W1870673602A5051077215 @default.
- W1870673602 hasAuthorship W1870673602A5058359283 @default.
- W1870673602 hasAuthorship W1870673602A5059063118 @default.
- W1870673602 hasAuthorship W1870673602A5062295987 @default.
- W1870673602 hasAuthorship W1870673602A5064884168 @default.
- W1870673602 hasAuthorship W1870673602A5072850546 @default.
- W1870673602 hasAuthorship W1870673602A5090839925 @default.
- W1870673602 hasConcept C126322002 @default.
- W1870673602 hasConcept C126894567 @default.
- W1870673602 hasConcept C143998085 @default.
- W1870673602 hasConcept C2776694085 @default.
- W1870673602 hasConcept C2777767877 @default.
- W1870673602 hasConcept C2780873365 @default.
- W1870673602 hasConcept C71924100 @default.
- W1870673602 hasConcept C90924648 @default.
- W1870673602 hasConceptScore W1870673602C126322002 @default.
- W1870673602 hasConceptScore W1870673602C126894567 @default.
- W1870673602 hasConceptScore W1870673602C143998085 @default.
- W1870673602 hasConceptScore W1870673602C2776694085 @default.
- W1870673602 hasConceptScore W1870673602C2777767877 @default.
- W1870673602 hasConceptScore W1870673602C2780873365 @default.
- W1870673602 hasConceptScore W1870673602C71924100 @default.
- W1870673602 hasConceptScore W1870673602C90924648 @default.
- W1870673602 hasIssue "3" @default.
- W1870673602 hasLocation W18706736021 @default.
- W1870673602 hasLocation W18706736022 @default.
- W1870673602 hasOpenAccess W1870673602 @default.
- W1870673602 hasPrimaryLocation W18706736021 @default.
- W1870673602 hasRelatedWork W2354070956 @default.
- W1870673602 hasRelatedWork W2361544313 @default.
- W1870673602 hasRelatedWork W2367148332 @default.
- W1870673602 hasRelatedWork W2377194436 @default.
- W1870673602 hasRelatedWork W2379797794 @default.
- W1870673602 hasRelatedWork W2387225332 @default.
- W1870673602 hasRelatedWork W2417819956 @default.
- W1870673602 hasRelatedWork W2435362053 @default.
- W1870673602 hasRelatedWork W247033857 @default.
- W1870673602 hasRelatedWork W943875344 @default.
- W1870673602 hasVolume "11" @default.
- W1870673602 isParatext "false" @default.
- W1870673602 isRetracted "false" @default.
- W1870673602 magId "1870673602" @default.
- W1870673602 workType "article" @default.